Aeolus Pharmaceuticals (AOLS)

[Werbe]

Share Structure as of 02/17/2017

Authorized Shares 200,000,000

Outstanding Shares 152,085,825

Float 53,784,744


Last news from March of this year killed the ticker .

"AEOL 10150 has been safe and well tolerated in 40 ALS patients and 9 healthy subjects and has demonstrated significant efficacy in animal models developed by BARDA and NIH as a broad spectrum medical countermeasure against radiation, sulfur mustard, soman, chlorine and phosgene gas exposure," said John L. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "We are grateful for NIH's continued support and commitment to move AEOL 10150 to approval in these indications. Aeolus and the US Government have invested more than $100 million to date and there are currently no treatments to address these very real threats that our country faces today. We also appreciate the collaboration, clear guidance and direction we have received from the FDA Division of Medical Imaging Products in establishing a pathway for approval under the Animal Rule."

About Acute Radiation Syndrome (ARS) and the Delayed Effects of ARS

AEOL 10150 is currently the only treatment in advanced development for Lung ARS. Statistically significant improvement in survival in both NHP and mouse models of Lung ARS have been demonstrated at HED's that have been safe and well tolerated in human safety studies. In June 2017, AEOL 10150 was granted Fast Track designation for Lung ARS by the FDA, and a special protocol assessment to reach agreement on the design of a pivotal ("adequate and well designed") study in the NHP will be submitted to the FDA shortly.

https://finance.yahoo.com/news/aeolus-aeol-10150-safe-well-120000983.html

On top of that AEOL 10150, they also created two more compounds, one which already has patents in Europe and Japan.

AEOL 11114 Is Subject of Michael J Fox Foundation Research Grant Program

Also this from 1 year ago on their AEOL 20415 compound..

Results from a new animal study show that Aeolus Pharmaceuticals’ anti-microbial compound, AEOL 20415, may protect the lungs from infections in cystic fibrosis (CF).

In the study, conducted in a mouse model of CF and led by Brian Day, PhD, vice chair of research at National Jewish Health, AEOL 20415 showed to be a potential treatment for antibiotic-resistant bacteria.

“This study confirms previous in-vitro studies indicating that AEOL 20415 is unique because it augments the body’s natural host defense system for fighting bacterial infection while limiting inflammation,” Day said in a press release.

“Currently available anti-inflammatory drugs work by suppressing the immune system, which can be counterproductive during active infection. AEOL 20415 has demonstrated efficacy in killing drug resistant clinical strains of Burkholderia cepacia and Pseudomonas aeruginosa isolated from cystic fibrosis patients and improving bacterial clearance while diminishing lung inflammation.” Day added.

Now about the insiders that were here, I am not sure what is going on anymore... Most had ties to the National Jewish Health. Very reputable... https://www.nationaljewish.org/home

Now on NationalJewish webpage, under startup companies, they show Aeolus Pharma.... They have direct ties with Aeolus as shown below.